MESENTECH - Key Persons
Barbara Yanni currently serves as an independent director of two public clinical-stage biopharmaceutical companies: Trevena (TRVN) and Vaccinex (VCNX). She is also a member of the Board of Supervisory Directors of Pharming Group NV and former director of Akcea (AKCA), Abionyx (ABNX) and Symic Bio.
David served as President and Chief Executive Officer of Zimmer Biomet (NYSE and SIX: ZBH) from 2007 to 2017. During his 16-year tenure with Zimmer Biomet revenues and capitalization grew by 500% to $7.7 billion, and 300% to $26 billion respectively.
Dr. Karpf is responsible for 12 INDs and 6 NDAs/WMAs. In particular, he led the phase 3 for Fosamax (Alendronate) at Merck. Thereafter, he was ran the bone area for Roche where he got Boniva (Ibrandonate) approved. Lastly, he led the clinical development of Transcon GH at Ascendis.
Job Titles:
- Managing Director of MedImmune ( AstraZeneca ) Ventures
Dr. Chen has over 20 years of experience in the biotech industry and played instrumental roles in two public companies (AnorMED and Cardiome). He has extensive experience in medicinal chemistry, process development, and analytical chemistry. He is the joint inventor of nine patents and co-author of 30 peer-reviewed journal articles.
Partner emeritus of Locust Walk Partners, Founding CEO and Director for Gloucester Pharmaceuticals (acquired by Celgene for $640M). Currently serves as Director of the T1D Exchange, a nonprofit organization accelerating therapies for type 1 diabetes.
Job Titles:
- Director of Metabolic Bone Diseases
Director of Metabolic Bone Diseases and Osteoporosis; formerly Chief of the Bone Tumor Service (osteogenic sarcoma, Ewing's sarcoma) at Memorial Sloan Kettering Cancer Center.
Karen has 25 years experience in regulatory affairs and development of novel drugs and medical devices. She has degrees in Chemistry and Pharmaceutical Sciences and has worked on a diverse portfolio of products from liposomes to lasers.
Job Titles:
- Chief Medical Officer at DiaMedica Therapeutics
Previously chief medical officer at DiaMedica Therapeutics, Edgewise Therapeutics and Agilis Biotherapeutics, neuromuscular franchise head at Roche and senior development roles at Wave Life Sciences Ltd., Idera Pharmaceutics, Inc., Alynylam Pharmaceuticals Inc. and Pfizer Inc. Prior to her pharma career Kirsten was an Associate Professor at SUNY Upstate and the University of Michigan. Kirsten obtained an M.D. from the University of Iowa College of Medicine and a Master of Science in Clinical Trial Design and Statistical Analysis from the University of Michigan, School of Public Health.
Job Titles:
- Chief Development Officer
Dr. Tam has 20 years of industrial experience in nonclinical and clinical drug development. Pat trained as a toxicologist and has expertise across early-phase drug development, pharmacology, bioanalytical method development and Phase I-II clinical program development and operations.
Paul has 35 years of R&D experience in academia and industry. As lead scientist on Amgen's denosumab program, Paul supported the molecule throughout its preclinical and clinical development programs, regulatory approval, and blockbuster commercial status. One of Amgen's most collaborative and published scientists, Paul managed >150 industry-academia collaborations and has authored >120 peer-reviewed manuscripts. Dr. Kostenuik is also an Adjunct Professor at the University of Michigan School of Dentistry, where chairs the Industrial Technologies Board of an NIDCR-sponsored Regenerative Medicine Consortium
30+ years leading discovery at Merck resulting in $80B+ in revenue from development of Singulair®, Vioxx®, Arcoxia®, Previcox®, Tredaptive® and Odanacatib. Recipient of Heroes of Chemistry award and two time recipient of Prix Galien.
Prior to joining at MGH, Baron was professor of orthopedics and cell biology at Yale University School of Medicine and editor-in-chief of the Journal of the International Bone and Mineral Society. Formerly head of bone diseases at Hoechst Marion Roussel (Aventis).